Review

Development of nucleic acid aptamer-based lateral flow assays: A robust platform for cost-effective point-of-care diagnosis

Tao Wang¹,²*, Lanmei Chen¹,³*, Arpitha Chikkanna¹, Suxiang Chen¹, Isabell Brusius¹, Nabayet Sbuh¹, Rakesh N. Veedu¹,²*¹

¹ Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth 6150, Australia.
² Perron Institute for Neurological and Translational Science, Perth 6009, Australia.
³ Guangdong Key Laboratory for Research and Development of Nature Drugs, School of Pharmacy, Guangdong Medical University, Zhanjiang 524023, China.

* These authors contributed equally.

Corresponding author: R.Veedu@murdoch.edu.au; Tel.: +61 8 9360 2803

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.11.26; Accepted: 2021.01.29; Published: 2021.03.05

Abstract

Lateral flow assay (LFA) has made a paradigm shift in the in vitro diagnosis field due to its rapid turnaround time, ease of operation and exceptional affordability. Currently used LFAs predominantly use antibodies. However, the high inter-batch variations, error margin and storage requirements of the conventional antibody-based LFAs significantly impede its applications. The recent progress in aptamer technology provides an opportunity to combine the potential of aptamer and LFA towards building a promising platform for highly efficient point-of-care device development. Over the past decades, different forms of aptamer-based LFAs have been introduced for broad applications ranging from disease diagnosis, agricultural industry to environmental sciences, especially for the detection of antibody-inaccessible small molecules such as toxins and heavy metals. But commercial aptamer-based LFAs are still not used widely compared with antibodies. In this work, by analysing the key issues of aptamer-based LFA design, including immobilization strategies, signalling methods, and target capturing approaches, we provide a comprehensive overview about aptamer-based LFA design strategies to facilitate researchers to develop optimised aptamer-based LFAs.

Key words: Aptamer, lateral flow assay, point-of-care, biosensor, sandwich assay, competitive assay.

1. Introduction

The effective detection of hormones, proteins and microorganisms in clinical samples, or contaminants in food or environment is crucial for disease control and public health management. Although various currently used analytical techniques including high-performance liquid chromatography (HPLC), mass spectrometry, ELISA assays allow highly sensitive and specific detection, their application depends heavily on trained personnel and sophisticated instrumental facilities [1]. Consequently, efforts have been made to develop simplified point-of-care test (POCT) devices featured by ease of use, rapid response, high affordability, and low analyte volume requirement [2]. Lateral flow assay (LFA), also known as immunochromatographic assay or strip test, is one of the most investigated POCT technologies [3, 4].

A typical LFA consists of three elements, the recognition element, reaction element, and signal transduction element. All of these elements are assembled on a paper strip including five components: the sample pad, conjugate pad, membrane, absorbent pad, and backing plate [5]. As shown in Figure 1, while the backing plate provides
support for strip assembling, all the other components are overlapping (2-3 mm) with each other sequentially to ensure that the liquid solution migrates through the LFA strip. In general, the sample pad is made of cellulose or glass fibre, to transport the sample under test to the following components of the strip [5]. The recognition agent (e.g. antibody)-conjugated reporter molecules (e.g. gold nanoparticles) are loaded on the second conjugate pad, which is commonly made of glass fibre, cellulose, polyesters or other materials being able to rapidly hydrate and release the labelled recognition agent upon meeting liquid samples. When the target analytes in the sample meet the recognition agent/reporter complex, a new complex (target/recognition agent/reporter) is created which then directed over to the test line. The test line is usually lineated on the nitrocellulose membrane and immobilized with target reacting molecules (e.g. aptamer, antibody or complementary oligonucleotides), to react with either the target analyte or the recognition agent and create a signal (the type of signal depends on the nature of the signalling elements) for qualitative or semi-quantitative analysis [3]. As the recognition agent/reporter complex is normally present in excess amount on the conjugate pad, the unbound recognition agent/reporter complexes can move further to the control line, which contains a capturing agent to recognize the unbound recognition agent/reporter molecules to validate the performance of the LFA system. The adsorbent pad is located at the end of the strip which serves as a blotting paper to maintain the flow direction of the liquid over the membrane [3].

The prototype design of LFA was first reported in 1956 by Plotz and Singer [6], which later gained explosive attention from the 1980s when the urine-based pregnancy test became commercially available [7]. Indeed, as a type of disposable paper assay with a user-friendly format, LFA fulfils the framework of ASSURED (affordable, sensitive, specific, user-friendly, robust, equipment-free and deliverable) for POCT evaluation proposed by the World Health Organization [8]. Consequently, the LFA industry rapidly progressed over the past three decades. As of 2018, the LFA industry has reached ~6.0 billion US dollars worldwide, and is expected to reach ~8.7 billion USD by 2023, with a compound annual growth rate of 7.7% [9]. As a key component, the recognition element of LFA has long relied on antibodies. Nevertheless, the integration of antibodies is hampered by a variety of factors, mostly due to its protein nature, such as irreversible temperature-induced denaturation, prolonged preparation time, difficulty in chemical modification, and importantly, inaccessible for nonimmunogenic and toxic molecules [10]. For improved LFA design, alternative recognition agents are of tremendous importance.

The rapid development in aptamer technology provides an opportunity to circumvent the obstacles faced by the antibody-based LFAs. Aptamers, first described in 1990, are short single-stranded DNA or RNA sequences that can bind to targets with high specificity and affinity [11] because of their unique ability to adopt three-dimensional shape in solution. Differing from traditional antibodies, aptamers have some obvious advantages including low batch-to-batch variation, prolonged shelf-life, low/no immunogenicity, and freedom to incorporate chemical modifications for enhanced stability and binding properties [12, 13]. Over the past decades, different types of aptamer-based LFAs (Apt-LFAs) have been exploited for target detection in various fields such as disease diagnosis [14, 15], environmental science [16], and food industry [17]. However, the practical application of Apt-LFA is still lagging behind that of antibody-based tests, with no Apt-LFA test kits being commercially available [18]. Development of highly sensitive and specific Apt-LFA depends on the improvement in some key technique issues, including the method for target and aptamer immobilization, recognition agents, and the signalling system. In this work, firstly, we provide an overview of Apt-LFAs, regarding the design strategies and recent advances. Then, via investigating the existing obstacles, opinions and suggestions for improved Apt-LFA development are provided.

2. Application of aptamers in LFA development

2.1 Wide applications of Aptamers for target detection

Aptamers, also known as “chemical antibodies”, can be used for nearly all antibody-based applications [19, 20]. However, compared with antibodies which are mainly used for recognizing biological materials such as proteins, aptamers show great flexibility to recognize virtually all substances including small molecules (e.g. antibiotics, metal ions), viruses and even whole cells [21, 22]. This is because unlike antibodies, the development of aptamers is conducted in vitro via a procedure called systematic evolution of ligands by exponential enrichment (SELEX) (Figure 2), to identify DNA or RNA aptamer sequences that are able to recognize the target of interests from a randomised (~10^16 members) nucleic acid library [11]. With such a high diversity, aptamers can be developed for any target. Importantly, SELEX
procedure can help developing aptamers that bind to low-molecular-weight compounds, which are not readily conducive to antibody generation. Taking fungicide malachite green as an example, because no antibody is available for such small molecular antibiotics, the detection of it has depended on time-consuming and expensive HPLC and liquid chromatography-mass spectrometry (LC-MS) assays [23] until the development of a 38-mer malachite green aptamer in 1999 [24], based on which, for the first time, an Apt-LFA for simplified malachite green residue detection became available [25]. Similarly, Apt-LFAs for the detection of various non-immunogenic targets such as apple stem-pitting Virus (ASPV) [26] and organophosphorus pesticides [27] have also been established.

Figure 1. Schematic illustration of a typical lateral flow assay strip. It includes five components that are assembled on a paper strip. After adding liquid samples to the sample pad (blue), it migrates from the conjugate pad, test line, and control line to the absorption pad. Target molecules are captured with a colour indicator in the test line, and the lateral flow system is validated by the control line.

Figure 2. Schematic illustration of SELEX protocol for aptamer identification. SELEX consists of a very defined iterative procedure, i.e. library preparation, target and library incubation, bound/unbound sequence separation, elution of target bound sequences, PCR amplification, and single-stranded DNA separation (for DNA aptamer) or transcription (for RNA aptamer). Differing from traditional antibodies, the development of aptamers is performed in vitro.

3. Existing Apt-LFA formats

The antibody-based LFA was introduced in clinical practice long before the invention of aptamer technique. Given the similarities between aptamer and antibody in terms of the tertiary structure-based target recognition, knowledge acquired from antibody-based biosensor design could be useful for Apt-LFA development. Over the past decades, various Apt-LFA approaches including sandwich formats, competitive formats, and other novel methods based on the structural and functional features of aptamers have been introduced, as described below.

3.1 Sandwich Apt-LFA

The sandwich assay method is the most used Apt-LFA, especially for the detection of large molecular weight analytes like proteins [30]. In a typical sandwich Apt-LFA, after loading samples to the sample pad, the target molecules are firstly captured by a detection aptamer (often conjugated with a reporter molecule) resulting in the formation of a reporter-conjugated aptamer/target complex on the conjugate pad. Upon migration to the test line, the target molecule in the complex can be recognized by a secondary affinity agent and forms a sandwich structure with the target molecules in the middle (between the reporter-conjugated aptamer and the secondary affinity agent). By far, three different types of sandwich Apt-LFAs have been proposed.

3.1.1 Sandwich Apt-LFA using dual aptamers

In 2009, Xu and colleagues introduced a
sandwich Apt-LFA for thrombin detection [30], with a format identical to the conventional antibody-based LFAs. As shown in Figure 3, a pair of aptamers targeting different sites of the thrombin molecule were employed. Firstly, one of the aptamers, namely the detection aptamer, was conjugated to the gold nanoparticles (AuNPs) via thiolation and loaded onto the conjugate pad, serving as the recognition element. The second aptamer was biotinylated and immobilized onto the test line via streptavidin-biotin binding (streptavidin was pre-coated onto nitrocellulose membrane), serving as a capturing aptamer. After thrombin containing samples are loaded and migrated to the conjugate pad by capillary action, a thrombin/AuNP-conjugated detection aptamer complex was formed. The complex then continued to migrate along the strip to the test zone, where the complex was captured by a capture aptamer, and resulted in the aggregation of AuNPs (show a characteristic red colour, Figure 3A). The excess complexes then passed beyond the test line and then captured by fixed oligonucleotide sequences complementary to a specific region of the detecting aptamer on the control line resulting in another red band. In the absence of thrombin, a distinct red band was shown only on the control line (Figure 3B).

Later, following a similar procedure, different sandwich Apt-LFAs were reported, to detect various types of targets ranging from proteins [31, 32], viruses [33] to whole cancer cells [34]. Indeed, with two different aptamers immobilized on the conjugate pad and test line respectively to recognize different sites of the target analytes, many of the reported assays demonstrate high specificity and sensitivity in both target spiked buffer and clinical samples (Table 1).

3.1.2 Sandwich Apt-LFA using a combination of aptamer and antibody

One of the major shortcomings of sandwich Apt-LFA is the difficulty in identifying dual aptamers targeting different sites of a target molecule, especially for small molecules with limited binding domains for aptamer recognition. To address this issue, in addition to improving the SELEX procedure for selecting aptamer pairs, the combined use of antibody and aptamer has been exploited. In 2017, this strategy was explored by Minagawa and colleagues for salivary α-amylase (sAA) detection [35]. In this work, using a 75-mer DNA aptamer as the detection aptamer (conjugated with AuNP for signal readout), and a commercial anti-sAA antibody loaded on the test zone for sAA/AuNP-conjugated aptamer complex capturing, the authors developed an aptamer/antibody sandwich LFA allowing specific sAA detection in 0.1% (v/v) human saliva. However, the incorporation of the unstable and expensive antibodies contradicts the advantage of the integration of aptamers in LFA. Therefore, the application and further commercialization of such a format may not be feasible.

3.1.3 Sandwich Apt-LFA using split aptamers

To address the issue of lacking dual aptamers for LFA development, the concept of split aptamers was introduced by exploiting the structural flexibility of aptamers [36, 37]. The mechanism of split aptamer design is based on the target-induced reassembling of aptamer fragments. As shown in Figure 5A, in the presence of target molecules, two separate aptamer fragments could regain the three-dimensional structure and recover the affinity property of the parent aptamer. By conjugating one fragment of the aptamer to a signal reporter (e.g. AuNPs) and immobilizing the other fragment onto the test zone (serving as capturing agent), a sandwich LFA could be created (Figure 5B).

The first split aptamer-based biosensor was developed in 2009. In this work, via designing separate segments of two aptamers, Zuo and colleagues developed an effective electrochemical assay for cocaine and ATP detection [38]. The idea of using split aptamers for biosensor development soon became popular, with various types of targets, including thrombin (exciton energy transfer-based fluorescent sensing) [39], 17β-estradiol (absorption-desorption colourimetric detection) [40], and D-vasopressin (electrochemical biosensor) [41]. In 2016, a sandwich LFA based on split aptamers was pioneered for ATP detection [42]. In this work, the authors designed a pair of split oligonucleotides based on a previously reported ATP aptamer. While the signalling element was produced via labelling one of the aptamer fragments onto AuNPs and loaded onto the conjugate pad, the test zone was prepared by adding the second aptamer split onto the nitrocellulose membrane via streptavidin-biotin interaction. The developed Apt-LFA displayed a linear concentration-signal response within a wide range from 0.5 nM to 5 mM. When tested with solutions spiked with other nucleotides, including UTP, CTP and GTP, non-specific detection was not observed.

Notably, the application of split aptamers has been especially useful in the area of small molecule detection. As previously discussed, many of the small molecules are either not compatible with antibody development or lack a second binding site for dual aptamer identification. Theoretically, a split aptamer pair can be designed by dividing any aptamer into two separate fragments. However, split aptamers
generated from different cutting sites of the parental aptamer could display vastly different binding affinities [43]. Although investigations have been conducted to elucidate the influence factors for optimised split aptamer design [36, 43], a general principle is still not available. As suggested, to ensure the efficiency of split aptamer-based biosensors, the split sites have to be experimentally tested [43].

In conclusion, although both combined aptamer/antibody and split aptamer strategies have been exploited in recent years, dual aptamer-based sandwich LFA is preferred for highly-sensitive and specific LFA development. Further progress in aptamer identification techniques including the usage of efficient and diverse initial libraries (e.g. G-quadruplex library) [44], next-generation sequencing (NGS) based candidate identification [45], as well as rational counter selection strategies (e.g. using aptamer binding sites inhibitors) [46] would help to facilitate the development of high-quality dual aptamer-based LFA.

### 3.2 Competitive Apt-LFA

Competitive assay (also termed inhibition assay) represents another option when dual aptamers for a target are not available. Two types of competitive assays have been mostly exploited, with immobilizing either target molecules or oligonucleotides partially complementary to the aptamer to the test one to compete for the binding of target molecules to the aptamer. To our knowledge, there is only one exception reported where the aptamer was directly immobilized on the test line [47].

---

**Figure 3. Schematic illustration of the dual aptamer-based sandwich Apt-LFA.** (A) In the presence of target molecules, the targets firstly bind to the detection aptamer and create a target/aptamer/reporter complex. When passing through the test line, the target/aptamer/reporter complex is then captured by a capture aptamer immobilized on the test line and results in the aggregation of the signal reporter, while the unreacted complex and the free aptamer/reporter are captured by a complementary oligonucleotide sequence immobilized on the control line to validate the LFA system; (B) In the absence of target molecules, the aptamer/reporter conjugate passes beyond the test line and is captured by specific complementary oligonucleotide probe on the control line. In both cases, the excessive reagents are absorbed by the absorption pad.

**Figure 4. Schematic illustration of Apt-LFA using a combination of aptamer and antibody.**
Table 1. Representatives of aptamer-based lateral flow assays

| Format                      | Target                                                                 | Limit of detection | Sample matrix | Reporter       | Ref. |
|-----------------------------|------------------------------------------------------------------------|--------------------|---------------|----------------|------|
| Sandwich assay              |                                                                        |                    |               |                |      |
| Aptamer pair-based sandwich assay | β-conglutinin                                                    | 8 fM               | PBS           | FeO@AuNPs      | [17] |
|                            | Creatine kinase MB                                                     | 0.63 ng/mL (7.5 pM) | Artificial serum | Fluorescent sphere | [15] |
|                            | Exosomes                                                               | 1.4 × 10⁹ exosomes/µL | PBS           | Au@Pd Nanopopcorn | [14] |
|                            | Salmonella Typhimurium                                                 | 10⁷ CFU/mL         | PBS           | AuNPs          | [108]|
|                            | Escherichia coli O157:147                                              | 10⁷ CFU/mL         | PBS           | AuNPs          | [108]|
|                            | Chikungunya virus,                                                    |                    | PBS           | Magnetic beads  | [33] |
|                            | Tick-borne encephalitis virus                                          |                    | PBS           |                |      |
|                            | Staphylococcus aureus                                                 | 10⁷ CFU/mL         | PBS           | AuNPs          | [108]|
|                            | E.coli                                                                 | 300 cells          | PBS           | Qdots          | [69] |
|                            | Ramos cells                                                           | 800 cells (strip reader) | PBS          | AuNPs          | [34] |
|                            | Thrombin                                                              | 2.5 nM             | NaCl–Na₂HPO₄ buffer | AuNPs        | [30] |
|                            | Vasin                                                                 | 39 pg/mL (0.86 pM)  | PBS           |                | [98] |
|                            | Rorgalite                                                             | 1.0 µg/mL (8.47 µM) | PBS           | AuNPs          | [109]|
|                            | Avian influenza H5N2                                                  | 1.27 × 10⁴ EID₅₀/mL (PBS) and 2.09 × 10⁴ EID₅₀/mL (duck’s feces) | PBS, duck’s feces | AuNPs | [110]|
|                            | Platelet-Derived Growth Factor-BB (PDGF-BB)                          | 1.0 nM             | PBS           | AuNPs          | [111]|
|                            | Thrombin                                                              | 1.5 nM             | PBS           | AuNPs          | [111]|
|                            | Thrombin                                                              | 0.85 nM            | PBS           | AuNPs          | [112]|
|                            | Human odontogenic ameloblast-associated protein                       | 8.32 nM (PBS), 14.59 nM (saliva) | PBS, Human saliva | AuNPs | [113]|
|                            | Vasin                                                                 | 0.173 nM           | Tris buffer   | AuNPs          | [31] |
| Aptamer and antibody-based sandwich assay | IgE                                                                  | 0.13 ng/mL (0.65 pM) | PBS           | HRP            | [114]|
|                            | α-amylase (sAA)                                                       |                    | Saliva        | AuNPs          | [35] |
|                            | Thrombin                                                              | 0.25 nM            | NaCl– Na₂HPO₄ buffer | Dual AuNP conjugation | [115]|
|                            | Cholera toxin                                                         | 10 ng/mL (0.387 nM) | PBS           | AuNPs          | [18] |
|                            | Platelet-derived growth factor BB (with antibody)                     | 1 ng/mL (4.15 pM)  | PBS           | AuNPs          | [116]|
|                            | Human osteopontin                                                    | 0.1 ng/mL (1.67 pM) | PBS           | AuNPs          | [117]|
|                            | Type-B aflatoxins                                                    | 0.16 ng/mL (0.51 nM) | PBS           | AuNPs          | [118]|
| Split aptamer-based sandwich assay | ATP                                                                 | 0.5 µM            | Urine         | AuNPs          | [42] |
| Competitive assay           |                                                                        |                    |               |                |      |
| Complementary sequences immobilized on the test line | Progesterone                                                        | 5 nM               | PBS           | AuNPs          | [119]|
|                            | Aflatoxin B1                                                          | 0.03 ng/mL (96 pM)  | PBS           | AuNPs          | [52] |
|                            | Zearealenone                                                          | 10 ng/mL (31.4 nM)  | PBS           | AuNP & peroxidase | [120]|
|                            | Listeria monocytogenes                                                | 53 cells/mL        | Minced chicken | aptamer-gated silica nanoparticles | [121]|
|                            | Chloramphenicol                                                       | 0.5 µg/mL (1.53 µM, visual), 0.0634 pg/mL (196 nM, quantitative) | PBS           | AuNPs          | [122]|
|                            | Aflatoxin B1                                                          | 10 ng/mL (32 nM, visual), 1.05 ng/mL (3.4 nM, quantitative) | PBS           | AuNPs          | [122]|
|                            | OTA, Hg²⁺, Salmonella, HBV,ST-2                                       | -                  | PBS           | AuNPs          | [123]|
|                            | OTA                                                                   | 1.86 ng/mL (4.6 nM) | PBS           | UCNPs          | [96] |
|                            | Exosome                                                               | 6.4 × 10⁹ particles/mL | Cell culture medium | AuNP | [124]|
|                            | Ampicillin                                                            | 2.71 ng/mL (7.76 nM) | Water         | Fluorescent dye HEX | [125]|
|                            | Ochratoxin A (OTA)                                                    | 4.7 nM             | Tris buffer   | Qdots          | [50] |
|                            | Ochratoxin A (OTA)                                                    | 0.45 nM (strip reader) | PBS, Wine | AuNPs          | [126]|
|                            | Ochratoxin A (OTA)                                                    | 1 ng/mL (2.48 nM)  | PBS           | AuNPs          | [127]|
|                            | Hg²⁺                                                                | 0.13 ng/mL (0.65 nM) | Water         | Fluorescence   | [51] |
| Target molecules immobilized on the test line | Kanamycin                                                            | 50 nM (visual), 4.96 nM (quantitative) | PBS           | Magnetic microspheres | [66] |
|                            | Chloropyrifos                                                        | 0.73 ng/mL (2.08 nM) | PBS           | Qdots, AuNS    | [128]|
|                            | Diazinon                                                             | 6.7 ng/mL (22 nM)   | PBS           | Qdots, AuNS    | [128]|
|                            | Malathion                                                            | 0.74 ng/mL (2.24 nM) | PBS           | Qdots, AuNS    | [128]|
|                            | Mercury ions                                                         | 5 ppb              | PBS           | UCNPs          | [16] |
|                            | OTA                                                                   | 3 ng/mL (7.4 nM)    | PBS           | UCNPs          | [16] |
|                            | Salmonella                                                           | 85 CFU/mL          | PBS           | UCNPs          | [16] |
|                            | β-Conglutinin                                                        | 9 fM (deoxynucleoside amplification) | PBS           | AuNPs          | [56] |
|                            | Cholera toxin                                                        | 51 ng/mL (1.82 nM)  | PBS           | AuNPs          | [18] |
|                            | Ampicillin                                                           | 130 pmole          | PBS           | AuNP           | [58] |
|                            | Aflatoxin B1                                                         | 0.1 ng/mL (0.32 nM) | Food, feedstuffs | Cy5          | [88] |
| Apatmers immobilized on the test line | CA125                                                                | 3.71 U/mL          | Serum         | AuNPs          | (DAB) [47]|
| Strand displacement & Target induced dissociation | HER2                                                                 | 20 nM              | Human serum   | AuNPs          | [62] |
|                            | Cortisol                                                             | 1 ng/mL (~2.7 nM)   | Artificial sweat | AuNPs          | [64] |

http://www.thno.org
### Table

| Format | Target                | Limit of detection | Sample matrix | Reporter              | Ref. |
|--------|-----------------------|--------------------|---------------|-----------------------|------|
|        | Ochratoxin A          | 6.3 nM             | PBS           | AuNPs, AgNPs          | [63] |
|        | Dopamine              | 65.2 nM            | Urine         | AuNPs                 | [67] |
|        | Cocaine/Adenosine     | 20 µM Adenosine; 10 µM cocaine | Tris acetate buffer | AuNPs | [65] |
|        | Aflatoxin B1          | 0.32 nM            | Corn sample   | Cy5 dye               | [129]|
|        | ATP                   | 69 µM              | PBS           | Rhodamine B dye       | [99] |
|        | E.coli                | 10 CFU/mL          | PBS           | AuNPs-DNA probe       | [130]|
|        | Salmonella            | 10 CFU/mL          | PBS           | AuNPs                 | [131]|
|        | Thrombin              | 6.4 pM             | NaCl− Na₃C₆H₅O₇ | AuNP/HRP              | [132]|

**Figure 5.** Schematic illustration of target-induced aptamer reassembling and split aptamer-based LFA. (A) In the presence of target molecules, two fragments of an aptamer could regain the original structure of the aptamer; (B) Overview of the split aptamer-based LFA.

**Figure 6.** Schematic of target induced dissociation (TID). Upon binding to target molecules, aptamer sequences may undergo conformation change to accommodate the target molecule, which results in the dissociation of complementary sequences originally bound to aptamer regions undergoing structural change.

### 3.2.1 Competition between the target molecule and a complementary sequence for aptamer recognition

Upon binding to targets, an aptamer undergoes conformational changes to accommodate the target molecules by forming special structures including hairpin, stem-loop or G-quadruplex [48]. When the structural change occurs in certain regions of the aptamer sequence, the Watson-Crick base pairing between the aptamer and its complementary sequence could be interrupted, and result in the target-induced dissociation (TID; Figure 6) [49]. Theoretically, by immobilizing an oligonucleotide partially complementary to the aptamer sequence on the test zone, the existence of target molecules in a sample could be detected by monitoring the binding between the immobilized complementary sequence and the aptamer. As shown in Figure 7, in a typical TID-based competitive Apt-LFA, the conjugate pad is labelled with aptamer-conjugated reporters (e.g. AuNPs), which migrate after resuspension towards the test and control lines. In the presence of the target analyte, the target could compete with the complementary oligonucleotide sequence for aptamer recognition on the test line, and display a weaker or no signal (Figure 7A). In contrast, in the absence of the target analytes, the aptamer/reporter complex could be easily captured by the complementary sequence (immobilized on the test line) and display a strong band on the test line (Figure 7B). Notably, differing
from the sandwich assays, in a typical competitive assay, an increased intensity of the band at the test line reflects a decreased amount of target molecules in the sample.

In 2011, Wang and colleagues developed a competitive Apt-LFA based on the quantum dot (Qdot, a fluorescent reporter) technique for rapid and highly sensitive detection of ochratoxin A (OTA) [50]. The competition strategy was designed by labelling: 1. a poly-A tagged OTA aptamer/Qdot complex to the conjugate pad, and 2. a ssDNA sequence (DNA1) partially complementary to the OTA aptamer to the test zone. After the OTA/aptamer/Qdot complex was formed on the conjugate pad and reached the test zone, OTA in the complex started to compete with the DNA1 immobilized on the test zone for aptamer binding, and demonstrated a signal negatively correlated with the OTA concentration of the sample. As an assay control, a poly-T probe (DNA2) was pre-loaded on the control zone to capture the poly-A tagged detection aptamers existing in either the aptamer/Qdot or OTA/aptamer/Qdot complexes. Featured by a limit of detection (LOD) of 1.9 ng/mL (comparable to ELISA and fluorescence polarization immunoassay), the whole assay could be completed in 10 min. Later, the application of this type of competitive Apt-LFA was extended to the detection of antibody-inaccessible small molecules such as mercury [51] and aflatoxin B1 (AFB1) [52] from river water, wine, herb and corn samples, with the range of LOD from 0.1 ng/mL to 1 ng/mL (Table 1).

Although TID-based competitive Apt-LFA approach demonstrates great potential, it should be noted that it is hard to achieve high sensitivity and specificity. This is mainly because of the difficulty in the complementary oligonucleotide design. As reported, to obtain an ideal complementary sequence, the designed oligonucleotide has to be tested experimentally to ensure the dissociation constant is within a certain range (determined by both the aptamer and the target) [53]. For example, a short sequence with a lower degree of complementarity to the detection aptamer may result in a weak hybridization and thereby false-positive signals (weak or no band on the test line in the absence of the target); in contrast, a long oligonucleotide sequence with much stronger binding to the detection aptamer than the target may cause a false-negative signal (strong band on the test line in the presence of the target) [54]. Generally, to maintain a proper competition, a complementary sequence with the same or slightly lower affinity to the aptamer than the target is desired [54]. Apart from the difficulty in designing complementary sequences, controlling the optimised kinetics of the sequence hybridization and liquid flow represents additional obstacles for TID-based Apt-LFA. As reported, a minimum of 500 seconds is generally required for effective oligonucleotide hybridization [55], while in a typical LFA, the sample solution may pass the immobilized sequences in seconds. To solve these problems, another mode of competitive assay, exploiting the competition between the target molecules in sample solution and the target molecules immobilized on the membrane, has been more commonly exploited.

3.2.2 Competition between the target in sample and target immobilized on the test zone for aptamer recognition

As shown in Figure 8A-B, the basic principle of this type of competitive LFA is based on the competition between the target molecules in the sample and target molecules immobilized on the test line surface for aptamer binding. After the target containing samples are loaded to the sample pad and bound to the aptamer/reporter complex on the conjugate pad, the target/aptamer/reporter complex could continue to travel to the test line, where the same target molecules are pre-loaded. As the targets in the samples and targets on the test line display comparable binding affinity to the detection aptamer, a competition between them takes place, and results in the signal change in accordance with the amount of target molecules in the sample. Similar to the TID-based competitive assay, as the increase in target concentration in the sample results in less free aptamers to bind to the immobilized target molecules on the test zone, a reduced signal will be observed in the test line (Figure 8A). Based on this principle, in 2016, Jauset-Rubio and colleagues developed an Apt-LFA for β-conglutin detection [56]. Firstly, thiolated β-conglutin aptamers-conjugated AuNPs were prepared and loaded to the conjugate pad. Then, recombinant β-conglutin and ssDNA sequences fully complementary to the detection aptamer were added onto the test line and control line, respectively. As reported, with an assay time of merely 5 min, the authors achieved a LOD of 55 pM – 10 mM. Furthermore, subsequent modification via recombinase polymerase assisted signal amplification, the LOD could be reduced dramatically to 9 fM, similar to a previously reported sandwich Apt-LFA [17]. As for the control line, since the immobilized 94 nt ssDNA sequence was fully complementary to the detection aptamer, it displayed a much higher binding affinity than that of the β-conglutin molecule to the aptamer. Upon passing the control line, both the unbound aptamer/AuNP complex and the aptamer/AuNP/β-conglutin complex could be captured for LFA validation.
Figure 7. Competitive Apt-LFA with a partial complementary sequence of the aptamer on the test line. (A) In the presence of target molecules, the binding of target molecules to the aptamers inhibits the binding of aptamers to their partially complementary sequence and results in no/low signal on the test line; (B) In the absence of target molecules, the aptamer is captured by its partial complementary sequence and shows signals on the test line. In both cases, the control line is labelled with a complementary sequence of the aptamer to validate the flow system.

Figure 8. Competitive Apt-LFA with target molecules on the test line. (A) In the presence of target molecules, the target molecules in the sample and test line compete to bind the aptamer which results in no/low signal on the test line; (B) In the absence of target molecules, the aptamer is captured by the target molecules on the test line and shows signals. In both cases, the control line is labelled with a complementary sequence of the aptamer to validate the flow system.

It should be noted that the immobilization of expensive and unstable proteins on LFA membrane compromises the merit of Apt-LFA development. Consequently, this method is preferred for detecting low cost and highly stable small molecule compounds. Even so, immobilization of small molecules on membranes may lead to the conformational change of the molecule and results in the failure of aptamer-target recognition [57]. As a result, the binding capacity of the detection aptamer to the immobilized target molecules must be experimentally tested [58]. To solve this problem, in a pioneer study, Lars Kaiser and colleagues developed a cross-recognition aptamer-based competitive LFA for small molecule - ampicillin - detection [58]. Via an in silico analysis of the sequence homologies between ampicillin and C-reactive protein aptamers, the authors first identified an aptamer sequence displaying affinity to both ampicillin and C-reactive protein. Then, via immobilizing C-reactive protein onto the test line, and using the cross-recognition AuNP-conjugated aptamer for ampicillin detection, a competitive Apt-LFAs was developed. After incubation with samples and adding the mixture to the sample pad, in cases that no ampicillin was presented, the AuNP conjugated detection aptamer
would bind to the immobilized C-reactive protein on the test line and show a clear signal. In contrast, if ampicillin was present in the sample, a competition took place and resulted in a decreased signal on the test zone. Although a relatively low LOD was recorded in this work, it provides an alternative strategy for single aptamer-based small molecule detection. Indeed, via introducing a big molecule (e.g. protein), the problem associated with small-molecule immobilization could be effectively solved.

Importantly, although a computer-aided cross-recognition aptamer design was used in this work, theoretically, identification of cross-recognition aptamers simultaneously recognizing two (or more) targets is also achievable via designing proper counter selection during the SELEX procedure (only keeping aptamers that bind to both targets during selection while discarding the sequences that bind to none or only one of the targets). This cross-recognition aptamer-based competitive LFA therefore represents a versatile and transferable general approach for small molecule detection.

3.2.3 Other competitive Apt-LFAs

In addition to the commonly used competitive Apt-LFA as discussed above, in recent years, via exploiting the unique structure of aptamers, other competitive Apt-LFAs have also been practised. The adsorption-desorption colourimetric method previously used for aptamer-based in-solution tests represents a promising strategy [59]. As shown in Figure 9A, after binding to target molecules, the weak conjugation between aptamers and AuNPs (via physical adsorption) could be interrupted, resulting in the release of naked AuNPs. Similar to ethanol-based nucleic acid precipitation, in high concentration salt (e.g. NaCl, NaAc) solution, the surface charge and electrostatic repulsion of naked AuNPs could be masked and lead to their aggregation [60]. Since the colour of AuNP is strictly decided by its size (and the size of the aggregates), a clear red to grey/blue change could be observed [61]. Via this principle, Derosa and colleagues introduced a single aptamer-based LFA for HER2 detection, with streptavidin and cationic charged PDDA polymer on the test line and control line, respectively [62]. As demonstrated in Figure 9B, firstly, a weak non-covalent aptamer/AuNP conjugation was created by incubating 5'-biotin-conjugated HER-2 aptamers with citrated AuNPs (citrate was pre-coated to provide a negative charge to AuNP). Then the complex was added to the sample for a short incubation, followed by applying the solution on the sample pad of the LFA. When HER2 protein was present in the sample, the binding between HER2 and aptamers could lead to the release of the aptamers/HER2 complex from AuNPs and result in the release of free AuNPs (due to TID). When the loaded solution migrates to the test line, the biotinylated aptamer/HER2 complex could be captured by the immobilized streptavidin. As no AuNPs were attached to the aptamers, no colour signal could be detected. As the free AuNPs were covered by negatively charged citrate, they could be captured by the cationic charged PDDA polymer on the control line to validate the assay system. In contrast, when HER2 was absent from the sample, the biotin-aptamer/AuNP complex could be easily captured by streptavidin molecules on the test line and display a red signal.

![Figure 9. Schematic illustration of adsorption-desorption mediated Apt-LFA.](http://www.thno.org)
simple method for single-aptamer-based LFA, the success of this method relies heavily on the quality of the aptamer/AuNP complex. In addition to titrating the optimum density of aptamers to AuNPs, the adsorption force of aptamers to AuNPs needs to be optimized. This is because while a too faint adsorption may result in spontaneous release of aptamers and result in false positive readout, a too strong adsorption could prevent the release of aptamers from AuNP even in the presence of target molecules and result in false-negative results [63].

Following the same principle, Dalirirad and colleagues developed a modified adsorption-desorption colourimetric LFA for cortisol (a stress biomarker) detection from sweat [64]. As shown in Figure 10, similar to that in Derosa’s study, the aptamer/AuNPs conjugation (weak non-covalent binding) was prepared by incubating cortisol aptamers and AuNPs at room temperature for 2 hours. However, rather than capturing biotinylated aptamers by streptavidin, the test line was immobilized with cysteamine to capture the citrate stabilized AuNPs. After incubating the aptamer/AuNP complex with the sample, in the presence of cortisol, the conformational change of aptamers, caused by the binding between aptamer and cortisol, could interrupt the weak aptamer/AuNP conjugation and result in the release of the free AuNPs. After loading to the sample pad, followed by passing through the cysteamine (positively charged) immobilized test line, the naked AuNPs (precoated with negatively charged citrate) in the mixture could be captured and display red colour. In contrast, when cortisol was not present in the sample, the aptamer masked AuNP could not be recognized by the cysteamine and no colour could be detected on the test line. Similar to many other Apt-LFAs, the control line was labelled with an oligonucleotide sequence complementary to the aptamer to capture either the free aptamers or AuNP-conjugated aptamers for system control. As known, a significant disadvantage of the conventional competitive Apt-LFA lies in its signalling mode. Obviously, the occurrence of a new signal on the test zone in the presence of the target is preferred for visual detection over the gradually faded signal as observed with conventional competitive LFA. This study provides an example to produce a competitive Apt-LFA with a readout method similar to the sandwich LFA (occurrence of a new signal on the test zone in the presence of the target).

Over the past decades, considerable efforts have been made to solve the signalling drawback of conventional competitive LFAs. For example, in 2006, Li’s group developed a unique single-aptamer-based LFA for the detection of small molecules adenosine and cocaine [65]. As shown in Figure 11, firstly, the authors extended an adenosine aptamer by synthesising additional sequences complementary to two short thiolated ssDNA sequences. Then, through conjugating the two short sequences to AuNP surfaces, AuNP aggregates were prepared via crosslinking the aptamers and these two short sequences. As the addition of the adenosine led to the formation of adenosine/aptamer complex (dis-assembling the AuNP aggregates) and the release of the biotinylated short sequence/AuNP conjugates, a distinct red colour could be detected in the test zone (labelled with streptavidin). As the original aggregates could not migrate along the membrane because of the massive molecular weight, a dark colour could be observed on the boundary of the conjugate pad and the nitrocellulose membrane, serving as a test control.

Figure 10. Schematic illustration of adsorption-desorption based Apt-LFA.
In a more recent study, a TID based Apt-LFA was developed by Ou and colleagues for kanamycin detection, by hybridizing a kanamycin aptamer with a ssDNA sequence partially complementary to the aptamer (this ssDNA is referred to as cDNA herein) [66]. According to the design (Figure 12), in the presence of kanamycin, the binding of kanamycin to the aptamer resulted in the desorption of the cDNA. As the amount of the dissociated cDNA is positively correlated to the amount of kanamycin molecules in the sample, the kanamycin amount could be estimated by developing a nucleic acid-based sandwich LFA to detect the dissociated cDNA. As detailed in Figure 12, firstly, two short oligonucleotides complementary to either the 5′- or 3′-end of the cDNA were carefully designed. Then, these two sequences were conjugated to the AuNP reporter and the test line, respectively, to develop a sandwich assay for cDNA detection. Obviously, in the presence of cDNA (equals the presence of kanamycin), a clear AuNP band could be observed. The control line was conjugated with a sequence complementary to the 3′-end of the AuNP-labelled short sequence. After flowing through the control area, the excessive AuNP/oligonucleotide complexes could be detected for the lateral flow validation. As
expected, with the competition occurring in the solution (more sensitive than on strip), accompanied by the complementary nucleic acid-based sandwich LFA, a highly sensitive kanamycin detection was achieved. After a 20 min procedure, the recorded LOD reached 4.96 nM, which was much lower than the LOD (309 nM) proposed by the European Commission for kanamycin detection [66]. Recently, the potential of this assay was further confirmed by Shima and colleagues, with a LOD of around 65.2 nM for dopamine detection from urine samples [67].

4. The LFA membrane and strategies for aptamer immobilization

4.1 Nitrocellulose membrane

Although nitrocellulose membrane has been mostly employed for Apt-LFA development, it is worth noting that owing to its complicated and heterogeneous structure, the application of nitrocellulose membrane is affected by the potential towing effect and diffusion phenomena [68]. As shown in a recent study, the type, thickness and pore size of the membrane used in LFA determine not only the immobilization efficiency of affinity agents, but also the overall flow rate, directly affecting the performance of the developed LFAs [69]. For example, membranes with a smaller pore size, which generally have a longer migration time for aptamer-target reactions, should be considered for aptamers with a relatively low binding capacity or when a longer competition time is desired (e.g. for competitive LFA development) [69]. Furthermore, it was also found that the adsorption capacity, the porosity and humidity condition of the membrane directly affected the sensitivity and specificity of the developed LFAs [68]. Unfortunately, due to a lack of systematic investigation, the selection of the membrane generally follows the knowledge derived from antibody-based LFA. Given the different physicochemical properties of aptamers and antibodies, the optimised factors (e.g. thickness, pore size) for antibodies may not be suitable for aptamers. Therefore, for optimum apt-LFA performance, the influence factors of the membrane on LFA need to be comprehensively investigated.

4.2 Strategies for aptamer immobilization

4.2.1 Non-covalent strategies

Immobilization of aptamers onto membranes or signal reporters (e.g. AuNPs) is an essential procedure for Apt-LFA development. Although the detailed mechanism behind the immobilization of nucleic acids (or proteins) to nitrocellulose membrane (the most exploited membrane) is still unclear, this non-covalent, hydrophobic interaction-mediated binding has been practised since 1960, and constructs the basis of several popular molecular biology techniques such as Southern blotting (nucleic acid immobilization) and Western blotting (protein immobilization). Theoretically, aptamers can be directly immobilized onto nitrocellulose membranes by simply adding aptamer solution to the membrane. However, direct physical adsorption is not practicable because of the relatively loose conjugation, which causes desorption of aptamers from the membrane during liquid flow [70]. In addition, the random conjugation of aptamers to membranes may affect the tertiary structure of aptamers in an unpredictable manner, and compromise the binding property of the aptamer. Fortunately, although Apt-LFA is a relatively new concept, the development of antibody-based paper assays over the past decades has provided valuable knowledge in this aspect. To overcome the disadvantages associated with physical adsorption, various strategies previously established for antibody immobilization have been exploited.

The most reported non-covalent method for aptamer immobilization is based on the high binding capacity between biotin and streptavidin. Via conjugating biotin molecules at the end of aptamer sequences and incubating the resulting biotinylated aptamers with nitrocellulose membrane-immobilised streptavidin, a strong aptamer/membrane binding could be obtained. However, utilizing streptavidin protein compromises the merits of using nucleic acid-based aptamers to some extent due to the stability issue. To solve this problem, Su and colleagues introduced a microgel mediated immobilization method through coupling aptamers onto poly(N-isopropyl acrylamide) followed by entrapment of the aptamer/microgel conjugates onto the membrane [71]. As demonstrated, the aptamer/microgel complex could be steadily entrapped on the membrane due to its large size, without affecting the recognition ability of the aptamer. Other efforts such as the tandem repeating aptamer mediated immobilization was also practised for enhanced aptamer density and improved resistance to nuclease degradation [72].

4.2.2 Covalent bond-based aptamer immobilization

Both physical adsorption and biotin-streptavidin based aptamer immobilization cause uneven immobilization of aptamers onto the membrane surface, and potentially affect the consistency of LFA. In this aspect, the covalent immobilization strategy represents a potential solution. As observed, nucleic acids could covalently bind to the nitrocellulose membrane through ultraviolet (UV) light exposure
[73]. Indeed, via a 15 min 254 nm UV light exposure, covalent immobilization of aptamers to nitrocellulose membrane could be achieved [69]. However, the naked aptamer-mediated immobilization could cause a flat immobilization pattern and potentially affect the binding affinity of the aptamer. To solve this problem, the authors further labelled an amine-C6 linker to the 5’-end of the aptamer to serve as a tethering point. After UV exposure, the aptamer could stand vertically away from the membrane surface and maintain its original structure. Although representing a simplified method, immobilization of aptamers via UV light may induce intramolecular structural changes by thymine dimerization, thereby affecting the reliability of the developed Apt-LFA. As a result, this strategy has rarely been practised in recent years. The aldehyde-amine-based covalent immobilization introduced by Pelton’s group is a more practical strategy [74]. Firstly, the authors pre-modified the membrane with aldehyde groups. Then, via incubating amine-conjugated aptamers, a covalent immobilization was achieved. Very similar to the streptavidin-biotin based immobilization, this method is featured by both simplicity and reliability. Importantly, such aldehyde-amine based aptamer immobilization offers sufficient structural flexibility and ensures the formation of the intact tertiary structure of the aptamer for reproducible LFA detection. However, it is worth noting that apart from requiring pre-modification of aptamers via extra chemical modifications, systematic investigation of the surface chemistries of the membrane is often required for optimized immobilization results [74].

5. Signalling strategies of Apt-LFA

The signalling element is of critical importance for high-quality LFA development. Although AuNP has been widely used in LFA as a signal reporter, the recent progress in material science has provided many new candidate reporters for LFA design, via either visible readout (e.g. liposome-encapsulated dyes, silver nanoparticles, coloured latex beads, carbon) or indirect signal detection (e.g. magnetic particles, Qdots, organic fluorophores, upconverting phosphors). Generally, to be eligible for LFA development, a reporter molecule needs to show features including high stability, ease of modification for recognition probe conjugation, and importantly, without affecting the affinity properties of the immobilized recognition probes [75].

5.1 Apt-LFA with colourimetric readouts

The colourimetric change can be easily observed without using any additional instruments, and is therefore preferred for point-of-care LFA development. AuNPs with a diameter of 10-100 nm are the most employed optical indicators for Apt-LFA development and construct the basis of many well-cited Apt-LFAs, due to their high stability, intense visible colour, easy labelling and large-scale production [76]. As displayed by the first reported Apt-LFA for thrombin recognition, via incubating thiolated aptamers with AuNPs (Au-S bond), an aptamer-AuNP complex could be produced for signalling purpose [30]. However, the application of AuNP is affected by several factors. Firstly, the synthesis of AuNPs associated with expensive procedures. Secondly, the stability of the AuNP is dependent on the electrostatic repulsion between individual particles. Without careful optimization of the buffer system (in terms of ion type, ion concentration and pH) and aptamer concentration, irreversible AuNP coagulation is easy to occur [61]. Thirdly, the detection limit of AuNP-mediated visual detection is not satisfactory in many cases, especially for the detection of large particles (e.g. extracellular vesicles or viruses), as the signal intensity of AuNP is negatively affected by the volume ratio of AuNPs to target molecules [77]. Consequently, modifications have been made to further improve the sensitivity of AuNP-based LFA. One of these modifications involves the use of enzyme-mediated signal amplification. In a recent study, by immobilizing peroxidase (HRP) onto the surface of AuNPs, Parolo and colleagues designed a high-sensitive LFA facilitated by the commonly used 3,3’,5,5’-tetramethylbenzidine (TMB) mediated catalytic signal amplification [78]. As reported, up to one order of magnitude of sensitivity could be achieved without losing the simplicity of the LFA. However, as mentioned previously, the employment of enzymes (instability and high cost) could compromise the advantages of employing nucleic acid-based aptamer techniques.

The high-sensitive silver staining technique, involving the deposition of metallic silver onto the protein surface, is a simplified and potent signalling strategy. In one study, via using a mixture of silver lactate and hydroquinone, Vasily and colleagues significantly improved the LOD of an AuNP-based LFA by 15 times for potato leafroll virus detection [79]. Another way to enhance the optical sensitivity is through the addition of palladium (Pd). Recently, by combined application of AuNPs and Pd, Cheng et al. developed an aptamer nanoflower-based LFA. Via modifying the optical properties of the AuNPs, a dramatic shift of red colour into the near-infrared region was observed. Through a smartphone-based thermal reader application, the authors achieved a 71-fold higher sensitivity compared to the AuNP
alone control [14]. In another study, to improve the sensitivity of the current AuNP-based LFA, Zhu and colleagues developed a dual-reporter strategy [80]. As shown in Figure 13, this assay was characterized by two separate conjugate pads. The first pad was immobilized with streptavidin-labelled bigger AuNPs (41 nm), while the second pad was immobilized with biotin-labelled affinity agent/smaller AuNPs (13 nm) complexes. After adding target-containing samples, the target/affinity ligand/smaller AuNP complexes reached the test line first (due to their smaller size) and were captured by a second capture agent. When the slow running bigger streptavidin-labelled AuNPs later reached the test line and conjugated with the smaller AuNP aggregates via biotin-streptavidin linkage, an improved signal could be detected. As reported, this dual-reporter strategy achieved a LOD of 1 pg/mL for the high-sensitivity cardiac troponin I (hs-cTnl) protein, which was 1000-fold lower than an AuNP-based LFA using antibody [80]. Following a similar strategy, in 2016, the same group extended the application of this method to the magnetic nanoparticle-based LFA for highly sensitive and selective carcinoembryonic antigen detection [81].

The magnetic nanoparticle (MNP) represents a promising substitute for AuNP-based visual detection. Similar to AuNPs, MNPs of different size (and magnetite content) show different colour (due to different reflection spectra) [82]. However, unlike AuNPs, for which the dispersion can easily be affected by various physicochemical properties such as pH value and salt ions, the highly stable MNP makes the labelling process independent of experimental factors and suitable for various assay matrices. As demonstrated by the dual-reporter strategy-based LFA developed in Zhu’s group [81], the utilization of MNPs enabled a LOD of 0.27 ng/mL, comparable to the much more complicated electrochemiluminescence immunoassay (ECLIA) [81]. Importantly, the magnetic particle signals could be measured via the magnetic reader (measuring the change of magnetic field) for sensitive and low-background signal detection [83]. For example, to improve the currently approved AuNP-based LFA for Ebola virus screening (15% error margin), Yan and colleagues developed a Fe₃O₄ magnetic particle-based LFA [84]. As demonstrated, with a 30 min operation time, the author achieved a LOD of 1 ng/mL (calculated according to glycoprotein amount), which was around 100-fold more sensitive than the traditional AuNP-based LFA.

In addition to MNP, other materials such as latex beads have also been exploited. In 2013, to detect DNA molecules from plasma, Mao and colleagues developed a nucleic acid hybridization-based sandwich LFA [85]. As demonstrated, via using two separate nucleic acid probes and blue dye-doped latex beads, the developed assay system achieved a LOD of 3.75 fmol, similar to that of the AuNP system but with a much lower cost. Indeed, featured by lower cost, high uniformity, reproducibility and compatibility to various chemical modifications, latex beads represent a promising substitute of AuNPs. Notably, latex beads are very suitable for developing multiplexing LFAs, as latex beads with multiple colours are readily available. In a recent study [86], via employing latex beads labelled with two different colours, the authors developed a sandwich LFA for simultaneously detecting IgGs and IgMs of two different viruses in a single assay, opened a new avenue for the development of simplified devices for multiple viruses and/or bacteria detection. The main limitation of latex beads lies in their instability (reduced colour intensity due to leaking) in buffer solutions or when long-term storage is required. In recent years, although the progress in material science has enabled the development of latex beads with enhanced stability, as demonstrated by a recent brucellosis detection study led by Zhu [87], further improvement

---

**Figure 13. Schematic illustration of the dual-reporter strategies for enhanced signalling.** (A) the conjugate area consists of two conjugate pads. The first pad is immobilized with streptavidin-labelled bigger reporters while the second pad with biotin-labelled affinity agent/smaller reporter complex. (B) the smaller AuNPs flow faster and bind to the capturing agent on the test line; (C) the bigger reporters flow slower and bind to the smaller reporters (via streptavidin/biotin binding) for enhanced signalling.
in terms of signal intensity and stability is still required.

In conclusion, although featured by great simplicity and widely used for POC device development, the nature of visual detection inevitably compromises its sensitivity. This is especially true when high sensitivity is required, such as early-stage virus infection and foodborne pathogens detection (a zero-tolerance of foodborne pathogens is demanded by the food safety testing industry). Over the past decades, various novel non-visual detection approaches have been exploited, including fluorescent imaging and nucleic acid amplification-based Apt-LFA detection.

5.2 Fluorescence-based Apt-LFA signalling

Directly conjugating fluorophores onto aptamers is a straightforward method for fluorescence mediated signalling. To detect the faint amount of aflatoxin B1 (AFB1) from food, Chao et al. synthesized a cyanidin 5 (Cy5, a fluorophore) conjugated DNA aptamer for competitive Apt-LFA design, with standard AFB1 molecules immobilized on the test line for aptamer competition [88]. A semi-quantitative detection was achieved by comparing the fluorescent intensities of the test line and control line. However, although directly conjugating the fluorophore to aptamer obviates the necessity of utilizing extra reporters such as AuNP and latex beads, the direct application of fluorescent dyes is affected by low fluorescent intensities caused by photobleaching and metabolic/chemical degradation.

Research on high-performance fluorescence labelling has led to the development of photo-stable quantum dot (Qdot) based Apt-LFA. First introduced in 1980, Qdots are nano-sized particles (2-10 nm) of a semiconducting material [89]. Characterized by unique electronic and optical properties, Qdots display excellent auto-fluorescence, water solubility, and accessibility to various chemical modifications for enhanced signalling [89]. Similar to AuNPs, the optical property of Qdot is strictly determined by its size (and shape). It is possible to produce Qdots of any fluorescence colour from the same material by adjusting the dot size, which is useful for multiple targets detection. Over the past decades, Qdots have found their way in broad biomedical applications such as medical imaging and biosensor development [89].

Recently, to improve the sensitivity of foodborne pathogen detection, a sandwich Apt-LFA using red fluorescence-emitting Qdots was developed [69]. Briefly, biotin was firstly labelled to the 5'-end of the detection aptamer, followed by conjugating the aptamer to Qdots via streptavidin-biotin binding. To confirm the enhanced detection efficiency of Qdot-based Apt-LFA, a second LFA was prepared by replacing Qdots to AuNPs. Notably, facilitated by a portable 365nm UV lamp, the signal could be visualized by naked eyes. The subsequent comparison revealed that the Qdot-based LFA obtained a 10-fold higher sensitivity than that of the commonly used AuNP-based LFA (6000 E.coli/mL vs 600 E.coli/mL). Importantly, this high-sensitive detection could be further improved by employing an orange glass filter. Later, following a similar procedure, another Qdot-based LFA was developed by Wilkins and colleagues for N-terminal pro B type natriuretic peptide (NT-proBNP, cardiac biomarker) detection [90]. As demonstrated, via using blue coloured Qdots as reporters, the developed LFA was able to detect NT-proBNP with high specificity and sensitivity, ready for clinical translation. In another study, by conjugating an ochratoxin A (OTA) specific aptamer to Qdots, Xu and colleagues reported a Qdot-based semi-quantitative Apt-LFA [50]. As shown, through comparing the fluorescent intensity of the Qdots in the test zone and control zone, the authors achieved a LOD of 1.9 ng/mL, meeting the minimal limitation requirement of OTA detection in wines and juices as issued by the European Commission Regulation [50].

However, despite their small size, Qdots show poor migration (due to clumping) in nitrocellulose membrane [91], which represents a potential obstacle for Qdot-based LFA development. To solve this problem, a comprehensive comparison of the commonly used reagents (e.g. surfactant) for particle suspension was performed by Berlina and colleagues; it was found that adding high concentration (i.e. 5%) of Tween 20 could dramatically improve the mobility of Qdots on nitrocellulose membrane without compromising the detection efficacy, similar to earlier observations [92].

In addition to replacing AuNPs, a combinatorial application of AuNPs and label-free Qdots has been proven to be a plausible method for enhanced LFA design, as displayed by an avian influenza virus detection work led by Li and colleagues [93]. Differing from the commonly used virus detection strategy (detecting virus-initiated IgG and/or IgM) which saw a high probability of false-negative results (virus-initiated IgG or IgM takes up to 2 weeks to develop), the authors developed an AuNP-based LFA for more reliable virus detection by directly analysing the existence of protein markers of viruses. However, although this method enables direct virus detection, the relatively low amount of virus particles in body fluid, especially at the early stage of infection, puts forward to the requirement for ultrasensitive signal readout. To address this issue, the authors firstly
developed an AuNP-based sandwich LFA. Once the AuNPs aggregated at the test zone (in the presence of the virus), the AuNPs were dissolved in 0.15 M hydrogen chloride (HCl) and 0.8 M bromine (Br₂) to release gold ions, which were then transferred to a Qdot-containing microplate. As the gold ions have been confirmed to be able to quench the fluorescence of Qdots in a concentration-dependent manner [94], the concentration of the gold ions, and therefore the intensity of the AuNP band on the test zone, could be calculated. Surprisingly, by transferring the visual signal of AuNP to Qdot-based fluorescence analysis, the authors achieved a LOD of 0.09 ng/mL, up to 100-fold more sensitive than the original AuNP-based visual detection.

Apart from Qdots, the lanthanide-doped upconverting nanoparticle (UCNP), capable of converting near-infra-red excitation into the high energy visible region (hence its name: upconverting), represents another promising material for fluorescence-mediated LFA design. Differing from other fluorescent molecules, the UCNP do not display autofluorescence and photodegradation because of the infra-red region excitation, which constructs the basis for its wide applications ranging from deep-tissue bioimaging, nanomedicine, fluorescent microscopy, volumetric display to security labelling [95]. Recently, for high-sensitive OTA detection, Wang and colleagues introduced a UCNP-based competitive Apt-LFA [96]. As shown in this study, an OTA specific aptamer was conjugated to UCNP via a carboxyl linker. As the binding of OTA to the aptamer/UCNP complex competed for the binding between the aptamer and its partially complementary ssDNA sequence on the test line, a semi-quantitative OTA detection could be obtained by calculating the relative fluorescence intensity (test line value/control line value, excited by a 980 nm laser). With a LOD of 1.86 ng/mL in wheat and beer samples, this device displayed a similar sensitivity with a previously reported Qdot-based LFA [97]. In addition to small-molecule detection, the UCNP-based Apt-LFA was also useful for the detection of protein markers. Recently, Ali M et al. developed a sandwich Apt-LFA using UCNP mediated signalling for visceral adipose tissue-derived serine protease inhibitor (vaspin, an obesity and type 2 diabetes marker) detection [98]. With only 3 minutes processing time, this assay achieved a LOD as low as 39 pg/mL, more than 15 times higher than that of the previously reported AuNP-based Vaspin LFA [31]. However, as reported, the product and labelling procedures of UCNP could be laborious, and the reproducibility needs to be further improved to reduce the high batch-to-batch variation associated with UCNP-based LFA [31].

5.3 Aptamer-gated fluorophore nanoprobes

The recently developed aptamer-gated fluorophore detection represents another promising fluorescence signalling strategy. Theoretically, any aptamer can be modified with a hairpin structure to serve as a gate to trap fluorescent molecules into a porous particle [99, 100]. Upon target recognition, the gate can be opened as a result of the conformational change of aptamers, which leads to the release of the blocked fluorophores for signalling purposes. In a recent work, Ozalp and colleagues reported an aptamer-gated silica nanoprobe-based LFA for ATP detection [99]. Firstly, according to a universal approach for gating aptamer design [100], the authors designed an ATP aptamer ended with a hairpin structure by adding a short sequence that was partially complementary to the 3’-end of the original aptamer. Then, the mesoporous silica particles, a widely used drug delivery material featured by large pore volume, were fabricated with rhodamine B (a fluorophore molecule) blocked inside the pores (via immobilizing the gating aptamer near the mouth of the pore). After that, the aptamer-gated fluorophore-loaded silica nanoparticles were immobilized onto the test line of the LFA. After ATP containing samples migrated from the sample pad to the test line, the binding between ATP and the aptamer could change the intramolecular conformation of the gating aptamers and disrupt their hairpin structure [101], which opened the silica nanopores (allowed the release of the captured fluorescent molecules) and resulted in reduced fluorescence signal in the test line. Because the release rate of the fluorophores was proportional to the concentration of target molecules in the solution [102], by quantifying the fluorescent signal on the test line before and after the LFA reaction, the concentration of the ATP molecules in the tested samples could be estimated.

Different from the commonly used LFA, the signalling mechanism of the aptamer-gated nanoprobe LFA relies entirely on the structural change of the aptamer upon target binding, without the requirement of a second aptamer sequence (as in sandwich assay) or immobilization of target analytes (which involves the difficulty in immobilization of unstable or hard-to-immobilized targets) or partially complementary sequences on the test line (involve the tricky step for complementary sequence design). This makes the aptamer-gated fluorescence detection a promising approach for simplified LFA design. And importantly, although previous efforts focused mainly on small molecule detection, as gating...
aptamers could be designed from aptamer sequences of any target, this strategy would be equally useful for detecting large molecules such as proteins, peptides or even whole microorganisms.

5.4 Signal amplification via nucleic acid amplification

Apart from increasing the signal intensity via fluorophores, the nucleic acid nature of aptamer enables developing high-sensitivity LFA via exploiting many of the established nucleic acid amplification techniques [22, 103]. Although PCR represents a standard method for nucleic acid amplification, the requirement of multiple procedures, reagents, and additional apparatus makes it impractical for LFA development. For practical LFA design, nucleic acid amplification strategies with more simplified procedures have been explored. The recombinase polymerase amplification (RPA) is such an example. As a type of isothermal reaction (reacting under constant temperature), RPA could be performed even in a water bath, making it an excellent candidate for developing low-cost and rapid POC tests [104]. In a recent study, an RPA facilitated competitive Apt-LFA was reported by Jauset-Rubio and colleagues for β-conglutin detection [56]. Differing from the common LFAs where the competition takes place on the membrane, to facilitate RPA-based signal amplification, the key competition step was designed to take place in a tube, where magnetic-bead conjugated β-conglutin molecules compete with β-conglutin protein in the test samples for aptamer binding. After incubation, aptamers bound to the bead-immobilized β-conglutin were amplified via RPA reaction for 15 min. As the primers used in RPA were featured by a tail end, all amplicons were flanked by ssDNA tails on 5' and 3' ends, which enabled the design of a sandwich LFA, via labelling a detection oligonucleotide (complementary to the 5' tail of the amplicon) onto AuNPs, and immobilizing a capture oligonucleotide (complementary to the 3' tail of the amplicon) onto the test line. When compared with the ordinary competitive Apt-LFA using identical sets of aptamer and target (LOD=55 pM), this RPA-based LFA (9 fM LOD) showed a more than 6,000-fold sensitivity. Although this RPA-based Apt-LFA facilitated high-sensitive target detection, there are concerns associated with its application. Firstly, as a type of competitive assay (the signal strength is negatively associated with the amount of target molecules in the samples), the presence of the target has to be assessed by comparing the band density of the test line with a target-free control. Though RPA is acceptable for normal competitive LFA, the systematic deviation of this multi-step assay could be dramatically magnified by various factors including the amplification bias, the error during aptamer elution, and the non-specific binding between the magnetic beads and aptamers, resulting in unwanted false negative/positive results. Secondly, the application of protein enzyme inevitably compromises the merits of using nucleic acid aptamers, as previously discussed. Alternatively, enzyme-free nucleic acid amplification techniques such as hybridization chain reaction (HCR) [105] and catalysed hairpin assembly [106] have also been exploited. Indeed, featured by a one-step procedure, ease to scale up, and no requirement for perishable protein materials, these enzyme-free strategies hold great potential for novel functional nucleic acid-based LFA design. For instance, via using HCR technique, a high-sensitive DNAzyme-based LFA for Pb2+ detection was developed by Chen and colleagues in 2013 [105]. In this work, a carefully designed substrate sequence was firstly hybridized with a DNAzyme sequence (the recognition agent for Pb2+ targets). Upon target recognition, the cleavage of the substrate sequence (by the DNAzyme) served as an input to trigger the HCR to produce biotin-tagged sequences. As these biotinylated sequences contain cohesive ends that could hybridize with a ssDNA probe, via conjugating the ssDNA probe on AuNPs, a sandwich LFA with LOD as low as 10 pM was developed. Although DNAzyme was used in this assay, as previously commented by a Nature publication, “If we succeed in developing a general aptamer triggering mechanism, then HCR amplification could be incorporated in sensors for a wide range of small molecules” [107]. Indeed, developing HCR triggers by modification of existing aptamers would dramatically improve the sensitivity of existing Apt-LFA.

6. Conclusion and perspectives

Since the development of the first LFA by Unipath in 1985, different types of LFAs have been reported for the detection of a wide range of target analytes including pathogens of infectious diseases (e.g. virus infection, malaria), toxins (e.g. endotoxins, snake venom), environmental pollutants (e.g. antibiotics, pesticides, heavy metals), small molecule drugs (e.g. cocaine) and metabolites (e.g. ATP) [133]. However, despite huge market potential and popularity, the conventional LFA faces challenges such as batch-to-batch variation and instability [133]. This is mainly due to the fact that conventional LFAs rely heavily on animal-derived antibodies, which display inter-batch variation due to the physiological variation among animals.

The rapid progress in aptamer (chemical antibodies) technologies over the past three decades

http://www.thno.org
provide a valuable opportunity to solve many of the obstacles faced by the conventional antibody-based LFAs [53, 134]. Aptamers are identified via in vitro procedures which do not require the use of animals, and compatible with chemical modifications [11]. This not only allows developing aptamers against non-immunogenic molecules (i.e. metal ions) or toxic molecules (e.g. toxins) that are not feasible for animal-based antibody development, but also, allows exploiting various nucleic acid-based analytical techniques (e.g. displacement assays, non-enzyme amplification techniques). Importantly, while the application of antibodies is limited to close to physiological conditions, aptamers could be selected and applied in non-physiological conditions akin to the real-world application (e.g. detecting reducing agents). These features, together with high affinity, small size, superior stability, ease of synthesis and freedom to incorporate chemical modifications, collectively make aptamers excellent recognition agents for biosensor development [135]. Furthermore, the aptamer technique allows identification of targets even when detailed knowledge about the target is not available. The recently developed Cell-SELEX is an example [136]. By employing intact cells as targets, coupling with optimized selection controls, Cell-SELEX allows researchers to identify aptamers to target cells in the absence of information about their surface structure which is very useful for the detection of new infectious diseases. Accordingly, aptamer industry reaches 245 million USD by 2020 with a compound annual growth rate of ~17.9% and there is a huge potential for the application of aptamers in LFA for POCT development [137].

However, it should be noticed that changes in assay conditions such as metal ions, buffer system and pH value could dramatically affect the binding property of aptamers and cause reduced detection efficiency [138, 139]. As demonstrated by a recent study, when an aptamer-based sensor was tested under different settings, compared with PBS (where the aptamer was identified), the binding affinity of the aptamer could be reduced significantly from 32.49 nM to 1964.4 nM in 50% beer [140]. Consequently, incorporating chemical modifications (e.g. 2'-amino pyrimidine, 2'-fluoropyrimidine, 2'-O-methyl and locked nucleic acid) to stabilize the tertiary structure of aptamers, or developing aptamers under the intended assay conditions rather than the commonly used buffer systems (e.g. PBS) are highly recommended [11].

Based on the nucleic acid nature of aptamer, various types of competitive Apt-LFAs have been introduced. Among them, the target molecule (on the test line) mediated aptamer competition is generally preferred. However, it does come with additional costs (for target immobilization) and potential stability issues (depending on the nature of the target). It is worth mentioning that many of the published competitive Apt-LFAs involve the integration of additional bases at the end of the aptamers, with complementary sequences of the additional bases immobilised on the control line for assay validation. However, these tails not only potentially interrupt the binding capacity of the aptamer and resulting in reduced detection efficiency, but also raise concerns for control line design of the competitive Apt-LFA, especially when a low amount of aptamers were immobilized on the conjugate pad. In such a case, when the amount of targets was low in the sample, all the aptamers may bind to the immobilised targets or oligonucleotides, with no aptamer available for control line binding (results in invalid assay control). In contrast, a high target concentration may cause all the aptamers being occupied by target molecules in the sample and again, no aptamer would be available for control line binding. Therefore, for effective competitive Apt-LFA development, the amount of aptamers, competitive targets/competitive oligonucleotides, as well as the complementary sequences in the control line have to be experimentally tested [10]. In fact, as previously mentioned, for more effective experimental control, full complementary sequences of the aptamers could be immobilized at the control line for aptamer recognition.

Although aptamers are suitable for detecting small molecules which are not accessible to antibody development, to our knowledge, only limited efforts have been made in this area, with Apt-LFAs reported only for the detection of AFB1, E2, bisphenol A (BPA), ATP, p-amino hippuric acid, Ochratoxin A, dopamine, ampicillin, cocaine and mercury. This is mainly because of the difficulty in developing high-affinity and specific aptamers for small molecule recognition. Despite novel strategies such as the crosslink mediated reporter aggregation (Figure 11) and the cross-recognition aptamer-based detection [58] have shed light on this area, further investigation is still imperative for efficient small molecule detection. This is especially true given the growing interest in the small endogenous metabolites-based disease diagnosis.

As discussed above, the sandwich format is preferred for Apt-LFA development, with one aptamer immobilised at the test line and an additional aptamer linked to a signal reporter for target detection. However, in many cases, developing a pair of aptamers targeting different sites of a target is difficult, especially for small molecules with limited
binding motifs. Although the combined application of aptamers and antibodies offers opportunities for sandwich format LFA development, the inclusion of costly and less stable antibodies compromises the inherent advantages of aptamer-based LFAs. Applying split aptamers is an alternative solution for sandwich LFA design when only a single aptamer is available. However, splitting an aptamer into two separate fragments causes reduced binding properties as recorded in our recent LDL-R aptamer development [21]. As a result, selecting a pair of aptamers targeting different sites of the target is highly desirable for efficient Apt-LFA development. To this end, strategies such as employing high-efficiency initial libraries or blocking aptatopes (aptamer binding sites) have been suggested [11]. The recent integration of next-generation sequencing and computer-based machine learning approaches for aptamer identification also provides a great opportunity for efficient aptamer identification, by in-depth evaluation of the binding motif of aptamers against the target of interest [11].

Whilst various types of Apt-LFA have been developed over the past decades, it should be noticed that a commercial Apt-LFA device is still not available. The relatively low LOD can be the main reason for this shortfall. Although novel strategies such as integrating isothermal amplification techniques and fluorescent readers can dramatically improve the detection sensitivity of LFA, the involvement of additional procedures significantly compromises its simplicity. Therefore, further advances in reducing the complexity of the current signalling readout approaches are required to develop highly sensitive Apt-LFAs. Towards this, a smartphone-based portable quantitative Apt-LFAs powered by the ever-progressing telecommunication techniques and integrated image processing applications hold great potential for the development of novel Apt-LFAs with improved efficiency.

Acknowledgments

R.N.V acknowledges the funding support from the McCusker foundation through Perron Institute of Neurological and Translational Sciences, Department of Health Western Australia COVID-19 grant and Murdoch University. T.W also supported by Murdoch University commercial research funding and Perron early and mid-career researcher internal grants scheme.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Nguyen VT, Song S, Park S, Joo C. Recent advances in high-sensitivity detection methods for paper-based lateral-flow assay. Biosens Bioelectron. 2020; 152.
2. Lingervelt D, Koffijburg H, Kusters R, MJ H. Point-of-care testing in primary care: A systematic review on implementation aspects addressed in test evaluations. Int J Clin Pract. 2019; 73: e13902.
3. Hristov DR, Quijada CR, Marquez JG, Schifferli KH. Designing Paper-Based Immunoassays for Biomedical Applications. Sensors (Basel). 2019; 19(3): 594.
4. Liu R, McConnell EM, Li J, Li Y. Advances in functional nucleic acid based paper sensors. J Mater Chem B. 2020; 8: 3213-30.
5. Ye H, Liu Y, Zhan L, Liu Y, Qin Z. Signal amplification and quantification on lateral flow assays by laser excitation of plasmonic nanomaterials. Theranostics. 2020; 10: 4389-73.
6. Plotz CM, Singer JM. The latex fixation test. II. Results in rheumatoid arthritis. Am J Med. 1956; 21: 893-6.
7. Brucker MC, MacMullen NJ. What’s new in pregnancy tests. J Obstet Gynecol Neonatal Nurs. 1985; 14: 335-9.
8. Kosack CS, Page AL, Klatser PR. A guide to aid the selection of diagnostic tests. Bull World Health Organ. 2017; 95: 639-45.
9. [Internet] Köhler R. Lateral Flow Assays Market by Application (Clinical Testing (Pregnancy, Infectious Diseases (Mosquito, Influenza, STI, Hepatitis, TB), Cardiac Marker (Lipid Test) Veterinary, Food Safety), Technique, End-User - Global Forecast to 2025. https://www.marketsandmarkets.com/ Market-Reports/lateral-flow-assay-market-16701533.html
10. Miriam Jaussen-Kubio M-S, Abdulaziz S. Bashammakh, Abdulrahman O. Alyoubi, Ciara K.O’ Sullivan. Advances in aptamers-based lateral flow assays. Trends Anal Chem. 2017; 97: 14.
11. Wang T, Chen C, Larcher LM, Barreto RA, Veedu RN. Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development. Biotechnol Adv. 2019; 37: 28-50.
12. Wang T, Yin W, Alshamaileh H, Zhang Y, Tran PH, Nguyen TN, et al. A Detailed Protein-SELEX Protocol Allowing Visual Assessments of Individual Steps for a High Success Rate. Hum Gene Ther Methods. 2019; 30: 1-14.
13. Wang T, Gantier MP, Xiang D, Bean AG, Bruce M, Zhou SF, et al. EpCAM-Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. Theranostics. 2015; 5: 1486-72.
14. Cheng N, Song Y, Shi Q, Du D, Liu D, Luo Y, et al. Au@Pd Nanopopcorn and Aptamer NanoFlower Assisted Lateral Flow Strip for Thermal Detection of Esosomes. Anal Chem. 2019; 91: 13868-75.
15. Zhang J, Lv X, Feng W, Li X, Li K, Deng Y. Aptamer-based fluorometric lateral flow assay for creatine kinase MB. Microchem Acta. 2018; 185: 364.
16. Jin BR, Yang YX, He HY, Park YI, Lee A, Bai D, et al. Lateral flow aptamer assay integrated smartphone-based portable device for simultaneous detection of multiple targets using upconversion nanoparticles. Sens Actuators B Chem. 2018; 276: 48-56.
17. Zhengzong Wu DH, Enbo Xu, Aiqian Jiao, Muhammad Farhan Jahangir Chuhtai, Zhengyu Jin. Rapid detection of β-conglycinin with a novel lateral flow aptasensor assisted by immunomagnetic enrichment and enzyme signal amplification. Food Chem. 2018; 269: 5.
18. Frohnmeyer E, Tusche N, Sitz T, Herrmann C, Dahl GT, Schulz F, et al. Aptamer lateral flow assays for rapid and sensitive detection of cholera toxin. Analyst. 2019; 144: 1840-9.
19. Wang T, Philippovich S, Mao J, Veedu RN. Efficient Epidermal Growth Factor Receptor Targeting Oligonucleotide as a Potential Molecule for Targeted Cancer Therapy. Int J Mol Sci. 2019; 20.
20. Alshamaileh H, Wang T, Xiang D, Yin W, Tran PH, Barreto RA, et al. Aptamer-mediated survival RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells. Sci Rep. 2017; 7: 5898.
21. Wang T, Rahimizadeh K, Veedu RN. Development of a Novel DNA Oligonucleotide Targeting Low-Density Lipoprotein Receptor. Mol Ther Nucleic Acids. 2020; 19: 1580-8.
22. Park KS. Nucleic acid aptamer-based methods for diagnosis of infections. Biosens Bioelectron. 2010; 18: 179-88.
23. Rajamahendran R, Selva Sharma A, Ilangachelian M. New insights into the binding interaction of food protein ovalbumin with malachite green dye by hybrid spectroscopic and molecular docking analysis. J Biomol Struct Dyn. 2019; 37: 4292-300.
24. Grate D, Wilson C. Laser-mediated, site-specific inactivation of RNA transcripts. Proc Natl Acad Sci U S A. 1999; 96: 6313-6.
25. Stad SL, Ashwin H, Johnston R, Dallas A, Kazakov SA, Tarbin JA, et al. An RNA-aptamer-based assay for the detection and analysis of malachite green and leucomalachite green residues in fish tissue. Anal Chem. 2010; 82: 2562-60.
26. Komoroswiska B, Hasio-Jarzewska B, Minicka J. Application of nucleic acid aptamers for detection of Apple stem pitting virus isolates. Mol Cell Probes. 2017; 36: 62-5.
27. Li Wang XL, Qiang Zhang, Cunzheng Zhang, Yuan Liu, Kang Tu, Jian Tu. Selection strategies. RNA biology. 2016; 13: 1232-45.
28. Manochehy S, McConnell EM, Li Y. Unraveling Determinants of Affinity Enhancement in Dimeric Aptamers for a Dimeric Protein. Sci Rep. 2019; 9: 17824.
29. Xu H, Mao X, Zeng QX, Wang SF, Kawde AN, Liu GD. Aptamer-Functionalized Gold Nanoparticles as Probes in a Dry-Reagent Strip Biosensor for Protein Analysis. Anal Chem. 2009; 81: 669-75.
30. Raston NHL, Nguyen VT, Gu MB. A new lateral flow strip assay (LFSA) using a pair of aptamers for the detection of Vspain. Biosens Bioelectron. 2017; 93: 21-5.
31. Ahmad Raston NH, Gu MB. Highly amplified detection of visceral adipose tissue-derived serpin (vaspin) using a cognate aptamer duo. Biosens Bioelectron. 2015; 70: 261-7.

http://www.thno.org
Bruno JG, Carrillo MP, Richarte AM, Phillips T, Andrews C, Lee JS. Development, Theranostics 39. Liu JB, Liu Y, Yang XH, Wang KM, Wang Q, Shi H, et al. Exciton Energy 41. Du Y, Guo SJ, Qin HX, Dong SJ, Wang EK. Target-induced conjunction of split 35. Minagawa H, Onodera K, Fujita H, Sakamoto T, Akitomi J, Kaneko N, et al. Selection, 38. Zuo X, Xiao Y, Plasco KW. High specificity, electrochemical sandwich assays based 48. Han K, Liang Z, Zhou N. Design strategies for aptamer-based biosensors. Sensors 47. Pranav Tripathi AK, Manisha Sachan, Sameer Gupta, Seema Nara. Aptamer-gold 46. Shigdar S, Qiao L, Zhou SF, Xiang D, Wang T, Li Y, et al. RNA aptamers targeting 42. Zhu C, Zhao Y, Yan M, Huang Y, Yan J, Bai W, et al. A sandwich dipstick assay for 34. Han (Basel). 2010; 10: 4541-57. 58. Kaiser L, Weisser J, Kohl M, Deigner HP. Small molecule detection with aptamer 57. McKeague M, Derosa MC. Challenges and opportunities for small molecule aptamer 52. Birui Jin YY, Tianjian Lu, Feng Xu, Min Lin. Lateral flow aptamer assay for detection 65. Liu J, Mazumdar D, Lu Y. A simple and sensitive “dipstick” test in serum based on 63. Ranganathan Velu MCD. Lateral flow assays for Ochratoxin A using metal nanoparticles. Pathogens. 2014; 3: 341-55. 70. Christopher J. Garvey MSK, Michael P. Weir, Gil Garnier. Localisation of alkaline phosphatase in the pore structure of paper. Colloid Polym Sci. 2007; 295. 72. Rev P, Linas C, Pati P, Monot M,警告 F, Sadik M, et al. “Flows” and their generation by modified sandwich lateral flow immunoassay: proof of principle. Clin Chem. 2011; 57: 1732-8. 74. Su S, Nutriu R, Filippe CD, Li Y, Pelton R. Adsorption and covulant coupling of avidin-binging DNA aptamers onto cellulose. Langmuir. 2007; 23: 1300-2. 76. McConnell EM, Cozma I, Morrison D, Li YF. Biosensors Made of Synthetic Functional Nucleic Acids: Toward Better Human Health. Anal Chem. 2020; 92: 3274-9. 79. McVeigh CM, Taggart C, Goodwin H, Moxham J, McInnes R. A novel lateral flow immunoassay for detection of papillomavirus. J Med Virol. 2008; 80: 1159-63. 81. Sato J, Naito A, Tsujita S, Imagawa Y, Suzuki H. Quantum-dot-gold(III)-based dual-color flow immunoassay for berberine using a lateral flow microfluidic device. Biosens Bioelectron. 2011; 26: 1901-5. 83. Jacinto MJ, Trabuco JRC, Vu BV, Garvey G, Khodadady M, Azevedo AM, et al. A fast and sensitive immunoassay of human papillomavirus. Clin Chem. 2008; 54: 301-6. 87. Zhu MS, Jia YR, Peng LZ, Ma JF, Li XR, Shi F. A highly sensitive dual-color lateral flow immunoassay for brucellosis using one-step synthesized latex microspheres. J Microbiol Methods. 2008; 75: 311-5. 88. Wang YY, Xu H, Wei M, Gu HC, Xu QF, Zhu W. Study of superparamagnetic nanoparticles as labels in the quantitative lateral flow immunoassay. Mat Sci Eng C. 2018; 84: 311-5. 90. Rev P, Linas C, Pati P, Monot M,警告 F, Sadik M, et al. “Flows” and their generation by modified sandwich lateral flow immunoassay: proof of principle. Clin Chem. 2011; 57: 1732-8. 92. Berlina AN, Taranova NA, Zherdev AV, Vengerov YY, Dzantiev BB. Quantum dots for lateral flow immunoassay based on AuNP-SEMs. Biosens Bioelectron. 2007; 22: 2140-5. 93. Li X, Lu D, Sheng Z, Chen K, Guo X, Jin M, et al. A highly sensitive dual-color lateral flow immunoassay for brucellosis using one-step synthesized latex microspheres. J Microbiol Methods. 2008; 75: 311-5. 94. Sheng Z, Han H, Hu D, Liang J, He Q, Jin M, et al. Quantum dots-gold(III)-based indirect fluorescence immunoassay for high-throughput screening of APP. Chem Commun (Camb). 2009; 2599-61. 95. Chen L, Zhao Q, Wang H, Liang Z. A lateral flow sensor for aflatoxin B1 in food and feedstuffs. J Hazard Mater. 2010; 177: 243-50. 96. Wu SJ, Liu LH, Duan N, Wang WY, Yu QR, Wang ZP. A test strip for ochratoxin A detection of aflatoxin B1 in food using a lateral flow immunoassay based on the use of aptamer-modified fluorescence upconversion nanoparticles. Bioanalysis. 2017; 9: 3693-700. 97. Wang LB, Chen W, Ma WW, Liu LQ, Ma W, Zhao YA, et al. A fluorescent lateral flow immunochromatographic strip sensor for the detection of ciprofloxacin in milk. Anal Biochem. 2013; 45: 4999-5000. 98. Lu X, Lu D, Sheng Z, Chen K, Guo X, Jin M, et al. A fast and sensitive immunoassay of avian influenza virus based on label-free quantum dot probe and lateral flow strip test. Talanta. 2012; 100: 1-6. 99. Sheng Z, Han H, Fu D, Liang J, He Q, Jin M, et al. DAPT-chip: A novel lateral flow immunoassay based on AuNP-SEMs. Biosens Bioelectron. 2007; 22: 2140-5.
110. Kim SH, Lee J, Lee BH, Song CS, Gu MB. Specific detection of avian influenza H5N2 virus via a Sandwich Lateral Flow Strip Assay Using a Pair of Aptamers. Nanoscale Research Letters. 2018; 13: 122-8.

111. Qin CY, Wen W, Zhang XH, Gu HS, Wang SF. Visual detection of thrombin using a label-free lateral flow strip biosensor through aptamer-cleavage reaction with enzyme catalytic amplification. Biosens Bioelectron. 2014; 56: 192-7.

112. Zhang S, Zhao S, Wang S, Liu JH, Dong YY. Development of Lateral Flow Strip biosensor based on a catalytic DNA circuit. Chem Commun. 2013; 49: 123-5.

113. Liu GD, Garzon AS, Qiu LW. Lateral Flow Aptasensor for Simultaneous Detection of Platelet-Derived Growth Factor-BB (PDGF-BB) and Thrombin. Molecules. 2019; 24. 114. Chen N, Liu YJ, Mukama O, Han XB, Huang HL, Li S, et al. A signal-enhanced and specific lateral flow aptasensor for the rapid detection of PDGF-BB. Rsc Advances. 2020; 10: 18601-7.

115. Mukama O, Wu W, Wu J, Lu X, Liu Y, Liu Y, et al. A highly sensitive and specific lateral flow aptasensor for the detection of human osteopontin. Talanta. 2019; 210: 120624.

116. Zhao Z, Wang H, Zhai W, Feng X, Fan X, Chen A, et al. A Lateral Flow Strip Based on a Truncated Aptamer-Complementary Strand for Detection of Type-B Allatoxins in Nuts and Dried Figs. Toxins (Basel). 2020; 12. 117. Adjarianni MN, Alsager OA. Lateral flow aptasensor for progesterone: Competitive target recognition and displacement of short complementary sequences. Analytical Biochemistry. 2019; 587.

118. Sun SM, Zhao R, Feng SM, Xie YL. Colorimetric zeuralenone assay based on the use of an aptamer and of gold nanoparticles with peroxidase-like activity. Microchim Acta. 2018; 185.

119. Tao Wang obtained his PhD degree from Deakin University in 2015, and worked at Deakin University and Murdoch University as a research fellow since 2015. Tao Wang's research interests focus on cancer research and aptamer-based theranostics.

120. Yu Q, Zhao Q, Wang S, Zhao Z, Zhang S, Yin Y, et al. Development of a lateral flow aptamer assay strip for facile identification of theranostic exosomes isolated from human lung carcinoma cells. Anal Chem. 2020; 92: 1439-47.

121. Lanmei Chen received his PhD degree in Chemistry in 2008 from the School of Chemistry and Chemical Engineering of Sun Yat-Sen University (SYSU) under the supervision of Prof. Liang-Nian Ji. He was then appointed as a lecturer in Guangdong Medical University (GDMU). He became an Associate Professor at GDMU in 2014. He has been a visiting scholar in Precision Nuclear Acid Laboratory (Veedu Lab) at the Centre for Molecular Medicine and Innovative Therapeutics (CMMIT), Murdoch University from 2019 to 2020, and his research was focused on developing aptamer based lateral flow strips for precision disease detection during this period. After he returned to GDMU, he became a full-time professor. His current research interests include rational design, synthesis and mechanism studies of bioconjugated metal complexes and nanoparticles as targeted anticancer therapeutics.

122. Cheng N, Song Y, Fu Q, Du D, Luo Y, Wang Y, et al. Aptasensor based on fluorophore-quencher nano-pair and smartphone spectrum reader for on-site quantification of multi-pesticides. Biosens Bioelectron. 2018; 117: 75-83.

123. Shim WB, Kim MJ, Mun H, Kim MG. An aptamer-based dipstick assay for the rapid and simple detection of aflatoxin B1. Biosens Bioelectron. 2014; 62: 288-94.

124. Chen J, Zhou X, Zeng L. Enzyme-free strip biosensor for amplified detection of Pb^{2+} ions based on a catalytic DNA circuit. Chem Commun. 2019: 123-5.

125. Lin H, Fang F, Zang J, Su J, Tian Q, Kumar Kankala R, et al. A Fluorescent Assembly Reaction in Biosensing. Small. 2019; 15: e1902989.

126. Dong S, Shi J, Shi J, Wang Y, Zhao F, Sun J, et al. Aptamer-assembled dual gold nanoparticle conjugates. Clin Biochem. 2013; 46: 1734-8.

127. You ML, Huang HL, Zhang JY, Li S, et al. Fluorescent aptamer-based lateral flow biochip and lateral flow aptasensor for the detection of human osteopontin. Talanta. 2020; 210: 126-33.

128. Cheng N, Song Y, Fu Q, Du D, Luo Y, Wang Y, et al. Aptasensor based on fluorophore-quencher nano-pair and smartphone spectrum reader for on-site quantification of multi-pesticides. Biosens Bioelectron. 2018; 117: 75-83.

129. Shim WB, Kim MJ, Mun H, Kim MG. An aptamer-based dipstick assay for the rapid and simple detection of aflatoxin B1. Biosens Bioelectron. 2014; 62: 288-94.

130. Wang W, Zhao S, Mao Y, Feng Z, Liu X, Zeng L. A sensitive lateral flow biosensor for Escherichia coli O157:H7 detection based on aptamer mediated strand displacement amplification. Anal Chim Acta. 2015; 861: 62-8.

131. Fang Z, Wu W, Lu X, Zeng L. Lateral flow biosensor for DNA extraction-free detection of Salmonella based on aptamer mediated strand displacement amplification. Biosens Bioelectron. 2014; 56: 192-7.

132. Qin CY, Wen W, Zhang XH, Gu HS, Wang SF. Visual detection of thrombin using a strip biosensor through aptamer-cleavage reaction with enzyme catalytic amplification. Analyst. 2015; 140: 770-7.

133. Surakas Kasertikul MJ, Nam-Trung Nguyen. Challenges and perspectives in the development of paper-based lateral flow assays. Microfluid Nanofluidics. 2020; 24: 18.

134. Song Z, Mao J, Barrero RA, Wang P, Zhang F, Wang T. Development of a CD63 Aptamer for Efficient Cancer Immunohistochemistry and Immunofluorescence-Based Exosome Isolation. Molecules. 2020; 25.

135. Sarahi Sigold M, Michael O’Connor, Tao Wang, Dongxi Xiang, Hadi Al Shamaileh, Liang Qiao, Ming Wei, Shu-Feng Zhou, Yimin Zhu, Lingxue Kong, Santanu Bhattacharya, ChunGuang Li, Wei Duan. Aptamers as theranostic agents: modifications, serum stability and functionalisation. Sensors (Basel). 2013; 13: 14.

136. Kaur H. Recent developments in cell-SELEX technology for aptamer selection. Biochim Biophys Acta. 2018; 1862: 7.

137. Ruth Reid BC, Sook Jyoti Das, Sourav Ghosh, Tarun Kumar Sharma. Application of aptamers as molecular recognition elements in lateral flow assays. Anal Biochem. 2020; 593.

138. Xiang D, Shibigar S, Qiao G, Wang T, Kouzani AZ, Zhou SF, et al. Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. Theranostics. 2015; 5: 23-42.

139. Dongxi Xiang Sh, Andrew G Bean, Matthew Bruce, Wenzong Yang, Mortial Mathews, Tao Wang, Wang Yin, Phuong Ha-Lien Tran, Hadi Al Shamaileh, Roberto A Barrero, Pei-Zhou Zhang, Yong Li, Lingxue Kong, Ke Liu, Shu-Feng Zhou, Yingchun Hou, Aina He, Wei Duan. Transforming doxorubicin into a cancer stem cell killer via EpCAM-aptamer-mediated delivery. Theranostics. 2017; 7.

140. Emilia Schax ML, Thomas Scherer, Shimshon Belkin, Johanna-Gabriela Walter. Aptamer-based depletion of small molecular contaminants: A case study using ochratoxin A. Biotechnol Bioprocess Eng. 2015; 20: 10.

Author Biography

Tao Wang obtained his PhD degree from Deakin University in 2015, and worked at Deakin University and Murdoch University as a research fellow since 2015. Tao Wang’s research interests focus on cancer research and aptamer-based theranostics.
Arpitha Chikkanna received her Bachelor’s degree in Life Sciences in 2012 from Jain University, India. She then obtained her Master’s degree in Biochemistry in 2014 from Center for Post Graduate Studies from Jain University. Later, she worked as a research assistant at Centre for Earth Sciences (CEaS), Indian Institute of Science from 2015 until 2018. Since 2019, she has been pursuing her PhD degree at Murdoch University, Australia under the supervision of Assoc. Prof. Rakesh N. Veedu. Her current research focuses on development of novel RNA targeting therapies for tackling solid cancers and aptamer-based diagnostics.

Suxiang Chen received his Bachelor degree of Agriculture in 2010 in South China Agricultural University (SCAU). He then obtained his Master degree in Biotechnology (Advanced) and a second Master degree in Technology and Innovation Management from the University of Queensland (UQ) in 2013 and 2014 respectively. Later, he worked in Darui Biotechnology Co. Ltd and Gene Denovo Biotechnology Co. Ltd in Guangzhou, China as a core technician and technical support team member respectively. Since 2016, he has been pursuing a PhD degree at Murdoch University under the supervision of Assoc. Prof. Rakesh N. Veedu. He also worked in the Centre for Molecular Medicine and Innovative Therapeutics (CMMIT), Murdoch University as laboratory assistant (2016-2019) and research assistant (2019-2020) respectively. His current research focuses include the development of novel RNA targeting therapies for tackling type-2 diabetes and solid cancers.

Isabell Brusius completed her Bachelor’s degree in Molecular Biomedicine at the Rheinisches Friedrich-Wilhelms-University (Bonn, Germany) in 2019. During and after her studies, she gained several months of research experience both at home and abroad, including a three-month internship at Murdoch University (Perth, Australia) under supervision of Assoc. Prof. Rakesh N. Veedu. She is currently doing her Master’s degree in Biochemistry at the Julius-Maximilians-University (Würzburg, Germany) and plans to pursue a PhD in genetics.

Nabayet Sbuh received her Bachelor degree of Biomedical Sciences in 2015 at Curtin University of Technology in Australia. She then went to Murdoch University, Australia to obtain her Honours degree in Biomedical Sciences in 2018 under the supervision of Assoc. Prof. Rakesh N. Veedu and planning to proceed to PhD in 2021. In between her studies she also worked as research assistant at the Centre for Molecular Medicine and Innovative Therapeutics (CMMIT), Murdoch University in collaboration with Perron Institute for Neurological and Translational Science in 2020.

Rakesh N. Veedu is currently an Associate Professor and head of precision nucleic acid therapeutics laboratory at Murdoch University and Perron Institute for Neurological and Translational Science. He obtained his PhD in synthetic organic chemistry in 2006 from The University of Queensland, Australia under the supervision of Prof. Curt Wentrup after completing his MSc from Griffith University, Australia. He then continued his postdoctoral career under the supervision of Prof. Jesper Wengel at the Nucleic Acid Center, University of Southern Denmark in the field of nucleic acid chemical biology. Later in 2009, he was appointed as a Research Associate Professor within the Nucleic Acid Center. He then returned to The University of Queensland in mid-2010 and established Functional Nucleic Acid Theranostics research group. His current research is focused on developing novel synthetic gene targeting nucleic acid therapeutics and nucleic acid diagnostics against a range of rare and acquired diseases.